Eos Energy Enterprises Inc vs Smith & Nephew plc — how do they compare? Eos Energy Enterprises Inc trades at $4.28 (market cap $1.47B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Smith & Nephew plc is far larger — about 8.5× Eos Energy Enterprises Inc's market cap, and Smith & Nephew plc pays a 2.64% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | SNN | |
|---|---|---|
Market Cap | $1.47B | $12.50B |
Sector | Energy | Health |
52-Week High | $19.19 | $38.70 |
52-Week Low | $3.14 | $28.73 |
Enterprise Value | $1.81B | $15.53B |
Dividend Yield | — | 2.64% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.15, up 5.33% today, but faces significant financial challenges with a net income margin of -246.76% and negative cash flow from operations. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 per share loss. Technical indicators show a mixed picture with bullish overall signals but bearish moving averages, while analyst sentiment remains cautious with 70% hold ratings.
Despite revenue growth potential in the energy storage market, EOSE carries substantial risk due to persistent losses, high debt-to-asset ratio of 91.87%, and ongoing shareholder litigation. The consensus price target of $7.75 suggests upside potential, but investors should weigh the company's financial instability against its growth prospects in the competitive battery storage sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →